Price to book forward of Orchid Pharma Limited – NSE:ORCHPHARMA
NiveshIQ
NSE: ORCHPHARMA · Pharma
Orchid Pharma Ltd.
₹1,000.25▼ ₹1.20 (-0.12%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ORCHPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Orchid Pharma Ltd.
Orchid Pharma Limited is a pharmaceutical company that develops, manufactures, and markets active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India, with a product portfolio that includes oral cephalosporins, injectable cephalosporins, and antibiotics. The company exports its products to approximately 40 countries internationally and operates as a subsidiary of Dhanuka Laboratories Limited. In FY26, Orchid Pharma Limited reported a revenue of ₹605 Cr and a net income of ₹-179 Cr, indicating a decline in both revenue and profit. Despite this decline, the company has been focusing on strategic integration and innovation to drive future growth, with recent developments including strategic acquisitions and global rights consolidation. The compa
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹820.00 Cr +23.10% | ₹921.00 Cr +12.30% | ₹886.03 Cr -3.80% |
| EBITDA Margin | 13.29% | 12.60% | 1.69% |
| Net Profit | ₹91.00 Cr +97.80% | ₹99.00 Cr +8.80% | -102.00% |
| EPS | ₹18.05 | ₹19.65 | ₹3.37 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
🔒
Sign in to see AI summaries
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹304 Cr, PAT ₹3 Cr, EPS ₹0.54, EBITDA margin 5.2%. Growth context: revenue QoQ -2.5%, PAT QoQ +56.7%. Street verdict: miss, revenue surprise +32.0%, PAT surprise -82.4%.
Management commentary points to product launches, approvals, and therapy-mix improvement and geographic expansion and in...
FY26 (last completed FY): revenue ₹886 Cr, PAT ₹-2 Cr, EBITDA margin 1.7%, EPS ₹3.37. Year-on-year: revenue YoY -3.8%, P...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ORCHPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ORCHPHARMA alongside your other holdings
Unlock full ORCHPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Orchid Pharma Ltd.?
NiveshIQ detects active intelligence signals for Orchid Pharma Ltd. (ORCHPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Orchid Pharma Ltd.?
Orchid Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹507,317.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.